Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

B 006

Next Previous
Drug Profile

B 006

Alternative Names: Anti-CD30 monoclonal antibody-MCC-DM1 conjugate; anti-CD30-MCC-DM1; B006; Recombinant anti-CD30 humanised monoclonal antibody conjugate

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Pharmaceuticals Holding
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cutaneous T-cell lymphoma
  • No development reported Anaplastic large cell lymphoma; Hodgkin's disease

Most Recent Events

  • 28 Apr 2025 No recent reports of development identified for phase-I development in Anaplastic large cell lymphoma in China (Parenteral, Injection)
  • 28 Apr 2025 No recent reports of development identified for phase-I development in Hodgkin's-disease in China (Parenteral, Injection)
  • 30 Mar 2022 Shanghai Pharmaceuticals has independent intellectual property rights for B 006

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top